KiraGen advances glioblastoma program with patient-derived tumor studies
KiraGen is evaluating multiplex-engineered CAR-T cells in patient-derived tumor samples and brain-tumor models in mice.
News + perspectives
What we are building. What we are learning.
Company updates, scientific perspectives, publications, and milestones from KiraGen Bio.
Featured updates
Devon Shedlock, PhD, joins KiraGen as a scientific advisor
The former Poseida cell-therapy CSO brings experience in allogeneic CAR-T engineering, platform development, and clinical translation to KiraGen's scientific advisory team.
Musella Foundation awards KiraGen $50,000 for patient-derived GBM research
The venture philanthropy grant supports evaluation of KiraGen's engineered CAR-T candidates in patient-derived GBM tumoroids to help guide continued product development.
All updates
2026
11 updatesKiraGen advances glioblastoma program with patient-derived tumor studies
KiraGen is evaluating multiplex-engineered CAR-T cells in patient-derived tumor samples and brain-tumor models in mice.
Tessa Green's recent publications span tumor biology and machine learning
KiraGen's Head of Immunoinformatics contributed to three recent studies spanning tumor biology, single-cell analysis, and the reliability of biomedical machine learning.
KiraGen to present its GBM CAR-T strategy at the 2026 CAR-TCR Summit
Co-founder and CEO Aaron Edwards will present KiraGen's approach to multiplex engineering for durable CAR-T activity in glioblastoma on September 15 at the CAR-TCR Summit in Boston.
Devon Shedlock, PhD, joins KiraGen as a scientific advisor
The former Poseida cell-therapy CSO brings experience in allogeneic CAR-T engineering, platform development, and clinical translation to KiraGen's scientific advisory team.
KiraGen establishes a new laboratory home at Tufts Launchpad | BioLabs
KiraGen moved into Tufts Launchpad | BioLabs in downtown Boston, expanding its access to flexible laboratory infrastructure, shared resources, and a collaborative biotech community.
KiraGen presents its multiplex CAR-T strategy at ASGCT 2026
Co-founder and CEO Aaron Edwards presented KiraGen's approach to building allogeneic CAR-T cells with intrinsic resistance to multiple suppressive pathways during an invited ASGCT symposium.
KiraGen files additional U.S. provisional patent applications
Additional provisional filings related to engineered immune cells expand KiraGen's developing intellectual property portfolio around its platform and product programs.
KiraGen and Incite Labs advance CAR-T research in liposarcoma
An Incite Labs-supported collaboration will evaluate KiraGen's multiplex-engineered CAR-T approach in dedifferentiated liposarcoma models.
Musella Foundation awards KiraGen $50,000 for patient-derived GBM research
The venture philanthropy grant supports evaluation of KiraGen's engineered CAR-T candidates in patient-derived GBM tumoroids to help guide continued product development.
Ryan Murray's PhD research published in Nature Communications
KiraGen highlighted co-founder and CSO Ryan Murray's research on coordinated engineering against rejection and overlapping tumor suppression.
Yuvaan Tiwari Foundation invests in KiraGen Bio
The foundation joined KiraGen as an investor in support of durable cell-therapy approaches for brain cancers.
2025
9 updatesThe Cure Starts Now awards KiraGen $50,000 to advance CAR-T research for DIPG
The translational research grant supports development of suppression-resistant CAR-T cells for DIPG and diffuse midline glioma, extending KiraGen's approach into pediatric brain tumors.
KiraGen wins a LabCentral Ignite Golden Ticket
The award provides a $50,000 credit toward LabCentral laboratory space and a one-year fellowship, expanding KiraGen's access to infrastructure, support, and Boston's biotech community.
KiraGen selected for Nomic Bio's Omni 1000 proteomics grant
The award expands KiraGen's access to high-dimensional protein profiling, enabling deeper measurement of how engineered CAR-T cells respond to suppressive tumor signals.
Donald O'Rourke, MD, joins KiraGen as a scientific advisor
The Penn neurosurgeon and glioblastoma CAR-T investigator brings clinical, translational, and CNS-delivery expertise to guide KiraGen's brain tumor program.
KiraGen joins the inaugural LabCentral and C10 Labs AI BioHub
LabCentral and C10 Labs selected KiraGen for a cohort combining wet-lab infrastructure, computation, and company-building support.
KiraGen featured on The Sheekey Science Show
Co-founder and CEO Aaron Edwards discussed KiraGen's founding, solid-tumor barriers, multiplex engineering, and glioblastoma on The Sheekey Science Show.
KiraGen presents multiplex base-edited CAR-T data at ASGCT 2025
Co-founder and CSO Ryan Murray presented preclinical findings from KiraGen's five-edit CAR-T precursor during a GenScript exhibitor showcase at ASGCT 2025.
KiraGen selected for the Recode Edge '25 cohort
KiraGen was selected as one of ten companies from more than 200 applicants for Recode's healthcare AI program.
KiraGen selected as a Boston Regional Finalist in the HBS New Venture Competition
KiraGen was selected as a Boston Regional Finalist in the Harvard Business School New Venture Competition's Alumni Track.